Direkt zum Inhalt
Merck
  • [Immunotropic and antihypoxant therapy of experimental drug-sensitive and drug-resistant tuberculosis].

[Immunotropic and antihypoxant therapy of experimental drug-sensitive and drug-resistant tuberculosis].

Patologicheskaia fiziologiia i eksperimental'naia terapiia (2013-06-29)
D S Sukhanov, T I Vinogradova, S N Demidik, N V Zabolotnyh, S N Vasilieva, A L Kovalenko, M L Vitovskaya
ZUSAMMENFASSUNG

The results of pre-clinical research of cycloferon, remaxol and runihol on the model of experimental generalized tuberculosis, caused by the MBT with a different spectrum of drug sensitivity are presented. A considerable increase of the curative effect of the therapy with the used of cycloferon and remaxol. There was manifested the strengthening of lung clearance from the office, reducing the prevalence of specific inflammation in the lungs of the index of lung damage, stimulation of sorption and destructive ability of peritoneal macrophages, inhibited in the course of development of experimental tuberculosis infection. Runihol has no impact on the effectiveness of chemotherapy in the absence of a stimulating influence on the phagocytic function of the peritoneal macrophages.

MATERIALIEN
Produktnummer
Marke
Produktbeschreibung

Sigma-Aldrich
9-Oxo-10(9H)-acridinessigsäure, for HPLC derivatization, ≥99.0% (T)